Blueprint Medicines (BPMC)
(Real Time Quote from BATS)
$89.81 USD
-0.25 (-0.28%)
Updated Sep 24, 2024 01:16 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for Blueprint Medicines Corporation falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -506.98 | -557.52 | -644.09 | 313.88 | -347.69 |
Depreciation/Amortization & Depletion | -5.80 | 10.75 | 7.84 | 7.03 | 0.31 |
Net Change from Assets/Liabilities | -41.13 | -53.77 | -23.68 | -15.62 | 9.72 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 117.07 | 98.26 | 361.27 | 81.75 | 59.64 |
Net Cash From Operating Activities | -436.85 | -502.28 | -298.65 | 387.04 | -278.02 |
Property & Equipment | -16.06 | -8.92 | -3.09 | -3.16 | -14.01 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 290.10 | -140.33 | 35.38 | -431.09 | -2.45 |
Other Investing Activities | 0.00 | -0.29 | -258.15 | 0.00 | 0.00 |
Net Cash from Investing Activities | 274.04 | -149.54 | -225.86 | -434.25 | -16.47 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 21.34 | 8.20 | 50.72 | 617.76 | 341.04 |
Issuance (Repayment) of Debt | 97.93 | 553.61 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.04 | 0.00 | 0.00 | 0.00 | -0.40 |
Net Cash from Financing Activities | 119.23 | 561.81 | 50.72 | 617.76 | 340.64 |
Effect of Exchange Rate Changes | 0.20 | -0.21 | -0.89 | -0.35 | 0.02 |
Net Change In Cash & Equivalents | -43.38 | -90.22 | -474.69 | 570.20 | 46.18 |
Cash at Beginning of Period | 124.90 | 215.12 | 689.80 | 119.60 | 73.43 |
Cash at End of Period | 81.52 | 124.90 | 215.12 | 689.80 | 119.60 |
Diluted Net EPS | -8.37 | -9.35 | -11.01 | 5.59 | -7.27 |
Fiscal Year End for Blueprint Medicines Corporation falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 39.14 | 89.14 | -506.98 | -396.07 | -262.35 |
Depreciation/Amortization & Depletion | -2.41 | -0.38 | -5.80 | -1.39 | 7.26 |
Net Change from Assets/Liabilities | -70.01 | -43.20 | -41.13 | -51.53 | -54.50 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -116.30 | -147.06 | 117.07 | 91.07 | 56.16 |
Net Cash From Operating Activities | -149.59 | -101.51 | -436.85 | -357.92 | -253.44 |
Property & Equipment | -3.67 | -1.10 | -16.06 | -11.39 | -5.14 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -107.49 | 78.24 | 290.10 | 206.66 | 210.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -111.16 | 77.13 | 274.04 | 195.27 | 204.86 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 49.61 | 67.33 | 21.34 | 5.73 | 5.30 |
Issuance (Repayment) of Debt | 146.43 | -0.37 | 97.93 | 97.97 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 48.94 | 0.00 | -0.04 | 0.00 | 0.00 |
Net Cash from Financing Activities | 244.98 | 66.96 | 119.23 | 103.70 | 5.30 |
Effect of Exchange Rate Changes | -0.18 | -0.15 | 0.20 | -0.29 | 0.26 |
Net Change In Cash & Equivalents | -15.95 | 42.44 | -43.38 | -59.24 | -43.03 |
Cash at Beginning of Period | 81.52 | 81.52 | 124.90 | 124.90 | 124.90 |
Cash at End of Period | 65.58 | 123.96 | 81.52 | 65.67 | 81.88 |
Diluted Net EPS | -0.80 | 1.40 | -1.83 | -2.20 | -2.19 |